All In Biotech

NDA 020895 · Viatris

Viagra

Sildenafil Citrate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 14, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Mar 27, 1998

Approved uses

3

Original approval plus efficacy supplements

Registered trials

439

87 Phase 3, 20 recruiting

FAERS reports

60,910

33,452 serious, 4,495 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 29, 2024.

Sildenafil citrate tablets are indicated for the treatment of erectile dysfunction. Sildenafil citrate tablets are a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) ( 1 )

Mechanism: The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum. When sexual...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 11, 2014 Supplement 42 · Efficacy LetterLabel
  • Sep 19, 2002 Supplement 18 · Efficacy LabelLetter
  • Mar 27, 1998 Original approval · Type 1 - New Molecular Entity · priority review LetterLabelReview
3 products under this application
  • VIAGRA · SILDENAFIL CITRATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
  • VIAGRA · SILDENAFIL CITRATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
  • VIAGRA · SILDENAFIL CITRATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sildenafil" as an intervention, any sponsor and status, largest first.

All 439 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective10,621
  • headache5,105
  • dyspnoea4,383
  • erection increased2,999
  • diarrhoea2,910
  • fatigue2,797
  • nausea2,676
  • dizziness2,602
  • cough2,306
  • death2,187
  • pain1,820
  • malaise1,689

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004987
20051,340
20061,598
2007955
2008924
2009894
20104,072
20112,002
20122,790
20132,909
20143,394
20154,061
20164,002
20174,367
20183,396
20194,504
20203,692
20212,619
20222,638
20232,543
20242,613
20252,606
20262,004

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Viagra (Sildenafil Citrate)

2024 spending

$165K

Beneficiaries

92

398 claims

Per beneficiary

$1,792

$82.10 per unit

View as table
YearSpending
2020$2,054,229
2021$729,142
2022$531,483
2023$333,640
2024$164,848

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,268 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.